List view / Grid view
A new study has identified novel drug targets for heart failure, focusing on two major types of the condition. These findings could lead to more effective, targeted treatments for both heart failure subtypes.
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients.
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
Cancer Research UK, Cytovation, and the Norwegian Cancer Society have teamed up to advance the treatment of adrenocortical carcinoma (ACC). The collaboration will support the Phase II clinical trial of Cytovation’s innovative therapy, CY-101.
New study reveals that TLE6 protein deficiency causes male infertility in mice. These findings suggest potential genetic causes and future treatment avenues for male infertility.
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
